UNSPSC 41131719: Glycosylated hemoglobin assay

In this classification a glycosylated hemoglobin assay is a device used to measure the glycosylated hemoglobins (A1a, A1b, and A1c) in a patient's blood by a column chromatographic procedure. Measurement of glycosylated hemoglobin is used to assess the level of control of a patient's diabetes and to determine the proper insulin dosage for a patient. Elevated levels of glycosylated hemoglobin indicate uncontrolled diabetes in a patient US FDA regulates Glycosylated hemoglobin assay under 21 CFR 864.7470 and under FDA product code LCP.

UNSPSC 41131719 Glycosylated hemoglobin assay is a Commodity code that does not reflect the actual activity in recent state and local solicitations posted under it. The code nominally addresses a specific diabetes-monitoring blood test, yet the opportunities tagged to this code predominantly solicit offender drug testing, pre-employment physicals, forensic drug analysis, employment screening, and breath alcohol testing equipment—services and products wholly unrelated to hemoglobin assay analysis. Collin County Community Supervision and Corrections Department's RFP 2026-327 for offender specimen collection and drug testing (due July 23, 2026, estimated value $600,000) and Benton County, Oregon's RFP for urinalysis testing supporting the Family Treatment Court Program (due July 7, 2026) represent the closest functional alignment with laboratory testing workflows, though both address controlled-substance screening rather than glycemic monitoring. Pinellas County, Florida's procurement of certified drug reference standards (due April 23, 2026) and the City Colleges of Chicago's RFP for employment screening services including non-NIDA drug panels (due March 30, 2026) further illustrate the divergence. The code shows little relevant recent activity for the hemoglobin assay product line itself; state and local procurement activity under this tag is driven by criminal justice, occupational health, and forensic testing demand rather than diabetes care pathways.

The geographic spread spans Florida, Texas, Oregon, Nevada, and Illinois, with Florida and Texas showing the most recent volume. Beyond the misalignment between code and actual scope, issuing bodies include county corrections and community supervision departments, county health departments, state public safety offices, and municipal college systems. Representative solicitations in this period include Collin County's drug testing services RFP (Texas), Benton County's urinalysis RFP (Oregon), Seminole County's naloxone and drug deactivation systems IFB (Florida, due July 26, 2023), Clay County's physicals and drug testing IFB (Florida, due February 26, 2026), Collier County's medical director and drug testing RFP (Florida, due August 28, 2025), and Nevada Department of Public Safety's breath alcohol testing equipment bids (due February 12 and 17, 2026). The mismatch between code definition and opportunity scope suggests either a data-tagging error in the state procurement systems or a systematic misclassification at the point of posting. Firms pursuing glycosylated hemoglobin assay opportunities should not rely on this code to surface relevant work; the actual buying activity occurs under clinical laboratory testing, occupational health screening, and forensic analysis taxonomies.